Medivir AB (publ)
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MVIR-B.ST research report →
Companywww.medivir.com
Medivir AB (publ) researches, develops, and sells pharmaceuticals primarily for the treatment of oncology in Sweden and internationally. The company markets Xerclear for the treatment of labial herpes under the Zoviduo name. It also develops Remetinostat for treating MF cutaneous T-cell lymphoma, as well as basal cell carcinoma.
- CEO
- Jens Lindberg
- IPO
- 2000
- Employees
- 9
- HQ
- Huddinge, SE
Price Chart
Valuation
- Market Cap
- $402.33M
- P/E
- -4.51
- P/S
- 91.27
- P/B
- 2.09
- EV/EBITDA
- -4.82
- Div Yield
- 0.00%
Profitability
- Gross Margin
- -1467.11%
- Op Margin
- -1981.72%
- Net Margin
- -2024.07%
- ROE
- -37.65%
- ROIC
- -41.94%
Growth & Income
- Revenue
- $4.41M · -82.74%
- Net Income
- $-89,221,000 · -41.34%
- EPS
- $-1.60 · -33.33%
- Op Income
- $-87,354,000
- FCF YoY
- -109.71%
Performance & Tape
- 52W High
- $10.52
- 52W Low
- $6.92
- 50D MA
- $7.69
- 200D MA
- $8.35
- Beta
- 0.35
- Avg Volume
- 28.22K
Get TickerSpark's AI analysis on MVIR-B.ST
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our MVIR-B.ST Coverage
We haven't published any research on MVIR-B.ST yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate MVIR-B.ST Report →